Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib

BACKGROUND: Regorafenib is an oral small-molecule multikinase inhibitor approved in third or later line of treatment for patients with metastatic colorectal cancer (mCRC). Regorafenib has shown significant benefits in overall survival and progression free survival in two phase III trials compared to...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:World J Gastrointest Oncol
Prif Awduron: Ricci, Vincenzo, Granetto, Cristina, Falletta, Antonella, Paccagnella, Matteo, Abbona, Andrea, Fea, Elena, Fabozzi, Teresa, Lo Nigro, Cristiana, Merlano, Marco Carlo
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Baishideng Publishing Group Inc 2020
Pynciau:
Retrospective Study
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7081116/
https://ncbi.nlm.nih.gov/pubmed/32206180
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v12.i3.301
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg